← Back to Clinical Trials
Recruiting NCT06103370

NCT06103370 Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06103370
Status Recruiting
Phase
Sponsor Johns Hopkins University
Condition HIV Infections
Study Type INTERVENTIONAL
Enrollment 360 participants
Start Date 2025-10-28
Primary Completion 2028-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Peer-educator-based network

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 360 participants in total. It began in 2025-10-28 with a primary completion date of 2028-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness of a social network intervention to recruit people who inject drugs and their networks for HIV testing and linkage to HIV prevention and treatment services in Maryland. Study aims are to determine the effectiveness of a social network driven intervention to increase: * HIV testing (primary); * PrEP knowledge; * Uptake of HIV services and pre-exposure prophylaxis (PrEP); * Uptake of medication for opioid use disorder (MOUD) initiation. Eligible participants who access syringe service programs (SSPs) serving two counties in Maryland and their risk network members (NMs) will be recruited using an established network inventory and coupon recruitment method. When an index successfully recruits NMs, the index-NM cluster will be randomized to either a peer-educator intervention arm or an equal-attention control arm. Index participants randomized to the peer-educator intervention arm will complete a training program adapted with stakeholder input to context that emphasizes effective communication, frequent HIV testing, and awareness of evidence-based HIV prevention and treatment services. An important innovation to the network intervention will be training indexes to use and distribute HIV self-test kits and naloxone to their NMs. Index participants randomized to the equal-attention control arm will receive training sessions focused on the opioid overdose epidemic and will not include any training to serve as a peer educator. All participants (indexes and NMs) will complete study assessments at baseline and at 3 and 9 months. We will compare the peer-educator intervention group and the equal-attention control group on rates of HIV testing, knowledge of PrEP options and resources, and rates of initiation of HIV treatment, PrEP, and MOUD treatment since the previous assessment (past 3 or 6 months).

Eligibility Criteria

Inclusion Criteria: Inclusion criteria for index participants: * Aged 18 or older * Self-reported injection drug use in the prior month * Accessed services at the SSP in the prior 3 months * Willing to undergo training and attend weekly booster group sessions * Able to recruit at least 1 drug use Network Member (NM) into study * Willing to talk with peers about PWID topics such as HIV prevention and care * Not previously enrolled in the study as index or NM * English-speaking Inclusion criteria for network member participants: * Aged 18 or older * Self-reported injection drug use in the prior month * Have a valid coupon or able to recall the 3-digit ID number * Not previously enrolled in the study as index or NM * English-speaking Exclusion criteria: • Individuals lacking the capacity to consent

Contact & Investigator

Central Contact

Oluwaseun Falade-Nwulia, MBBS, MPH

✉ ofalade1@jhmi.edu

📞 410-550-6234

Principal Investigator

Oluwaseun Falade-Nwulia, MBBS, MPH

PRINCIPAL INVESTIGATOR

Johns Hopkins School of Medicine

Frequently Asked Questions

Who can join the NCT06103370 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06103370 currently recruiting?

Yes, NCT06103370 is actively recruiting participants. Contact the research team at ofalade1@jhmi.edu for enrollment information.

Where is the NCT06103370 trial being conducted?

This trial is being conducted at Baltimore, United States, Frederick, United States.

Who is sponsoring the NCT06103370 clinical trial?

NCT06103370 is sponsored by Johns Hopkins University. The principal investigator is Oluwaseun Falade-Nwulia, MBBS, MPH at Johns Hopkins School of Medicine. The trial plans to enroll 360 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology